Drug Profile
Research programme: reversed chloroquines - DesignMedix
Alternative Names: DM 1157; RCQ compounds; Reversed chloroquine; RevoquineLatest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator DesignMedix
- Class Quinolines; Small molecules
- Mechanism of Action DNA intercalators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Malaria
Most Recent Events
- 28 Mar 2023 Discontinued - Preclinical for Malaria in USA (PO)
- 28 Apr 2018 No recent reports of development identified for preclinical development in Malaria in USA (PO)
- 13 Apr 2018 National Institute of Allergy and Infectious Diseases plans a phase I trial for Malaria (In volunteers) in USA in April 2018 (NCT03490162)